Danone Blocks Infant Formula Batch in Singapore Amid Widening Cereulide Contamination Crisis

Spread the Message

Read Time:7 Minute, 36 Second

Danone has blocked a batch of infant formula produced for Singapore at the request of the country’s food regulator, as a widening contamination scare involving the toxin cereulide continues to ripple through the global baby milk market. Singapore’s Food Agency (SFA) has already ordered precautionary recalls of selected Danone Dumex Dulac 1 and Nestlé NAN HA1 SupremePro products after detecting the toxin in some samples, prompting urgent questions about infant formula safety, supply, and oversight.

What triggered the latest action?

Danone said it halted a specific batch of Dumex Dumex/Dulac formula manufactured for the Singapore market after SFA asked the company to block it as part of an ongoing investigation. The company stressed that its internal quality checks had not found cereulide or irregularities linked to Bacillus cereus, the bacterium that can produce the toxin.

The SFA’s directive follows earlier orders to recall two infant formula products – Nestlé’s NAN HA1 SupremePro and Danone’s Dumex Dulac 1 – after testing detected cereulide toxin.
Authorities in Singapore say the affected batches may have used the same raw ingredient as several previously flagged Nestlé formulas, pointing to a shared upstream supplier issue rather than a single brand-specific failure.

Financial markets reacted swiftly, with Danone’s shares dropping around 8–10%, at one point touching a near one‑year low, as investors digested the potential scope of the crisis.

What is cereulide and why is it a concern?

Cereulide is a heat‑stable toxin produced by some strains of Bacillus cereus, a bacterium associated with foodborne illness. Unlike many germs that are killed by standard cooking or pasteurisation, cereulide can withstand high temperatures, which makes contamination in processed foods particularly challenging once it occurs.

Health agencies describe cereulide poisoning as typically causing rapid‑onset nausea, vomiting, abdominal cramps and diarrhoea, often within hours of ingestion.
Young infants and immunocompromised children are considered at higher risk for severe outcomes; rare but serious complications can include injury to the liver, kidneys, muscles and brain, and in extreme cases, organ failure and death.
Singapore’s Communicable Diseases Agency has reported at least one local case of a child with mild symptoms likely linked to cereulide exposure after consuming affected formula; the child has recovered. Brazilian health authorities have separately reported two infants with persistent vomiting and diarrhoea after consuming recalled formula, underscoring the international reach of the issue.
How widespread is the infant formula contamination scare?

The incident in Singapore is part of a broader global infant formula crisis that began when Nestlé recalled infant nutrition products in multiple countries due to possible cereulide contamination linked to a specific ingredient supplier. Since then, several major manufacturers and regulators have taken precautionary steps.

Nestlé initiated recalls or sales suspensions for selected infant and follow‑on formulas across dozens of markets after internal and regulatory testing raised concerns about a shared ingredient used in these products.
Lactalis has recalled at least six batches of its Picot brand formula in France and other countries including Spain, China, Australia and Mexico, citing confirmed presence of cereulide in a supplied ingredient.
Singaporean authorities estimate that the implicated imported infant formula batches account for less than 5% of the country’s total infant formula supply, a figure intended to reassure families about overall availability.

In addition, Singapore’s SFA has directed a local manufacturer, SMC Nutrition, to halt exports of certain formulas that used the same suspect raw material, notifying importing countries to coordinate overseas precautions.

What are companies and regulators saying?

Danone, Nestlé and Lactalis have all emphasised that they are complying with regulators and prioritising safety, while also defending the robustness of their manufacturing controls. The crisis is testing public trust in brands that play a central role in infant nutrition worldwide.

Danone says all its infant formula products are manufactured under strict food safety and quality standards and undergo rigorous testing before leaving factories, with current controls showing products are safe and compliant with regulations.
The SFA and Singapore’s Communicable Diseases Agency state that they are working with healthcare providers to monitor potential cases of cereulide poisoning in children and that consumers should not feed recalled products to infants.
European regulators are also investigating the implicated ingredient supply chain, while food safety experts point out there is currently no harmonised European Union threshold for cereulide in foods, complicating risk assessment and enforcement.

Independent expert perspectives

Food safety and paediatric specialists not involved in the investigations say the events highlight vulnerabilities in globalised ingredient supply chains.

Dr. Aarti Mehta, a paediatrician at a large public hospital in Mumbai, notes that even when individual factories follow strict protocols, a contaminated common ingredient can create a “single point of failure” affecting many brands. She adds that parents should be informed but not alarmed, as most batches remain unaffected and regulatory systems are designed to act quickly when red flags appear.

Dr. Rajiv Nair, a food microbiologist at a national research institute, explains that cereulide’s heat stability means standard pasteurisation cannot remove it once present, so prevention must focus on controlling Bacillus cereus in raw materials and early processing steps. He stresses that better upstream surveillance, validated testing methods for cereulide, and clear international guidelines are crucial to reducing future risks.

What should parents and caregivers do now?

Health authorities in Singapore and other affected countries are urging parents to check product details carefully and seek medical advice if infants develop symptoms after consuming potentially contaminated formula. For families, the immediate priority is practical: ensuring infants receive safe, adequate nutrition while avoiding implicated batches.

Key steps recommended by health agencies and paediatric experts include:

Check product labels: Verify brand, product name, batch/lot number, country of origin and expiry date against official recall notices from local food safety authorities or the manufacturer’s website.
Stop using recalled products: If a formula matches the recalled batch details, stop feeding it to the child and follow official instructions, which may include returning the product or disposing of it safely.
Monitor for symptoms: Watch for sudden vomiting, nausea, abdominal cramps or diarrhoea after feeding; seek prompt medical care if symptoms occur, especially in very young or medically fragile infants.
Do not switch abruptly without guidance for vulnerable infants: For babies born prematurely, with chronic illnesses or on specialised formulas, consult the treating paediatrician or neonatologist before changing products.

Public health guidelines continue to emphasise that breast milk remains the optimal source of nutrition for most infants when available, but many families rely on formula for medical, practical or personal reasons. Experts caution against home‑made formula recipes or unregulated products, which may carry significant nutritional and safety risks.

What are the broader public health and policy implications?

The growing number of manufacturers caught up in the cereulide scare is prompting calls for stronger international coordination on infant formula oversight. The incident comes against the backdrop of recent supply disruptions and policy moves in markets like the United States, where authorities have been working to strengthen domestic formula manufacturing resilience after past shortages.

Several public health and regulatory issues are emerging:

Standard‑setting for cereulide: The absence of a clear EU‑wide threshold and limitations in laboratory testing make it harder to define what levels of cereulide constitute an unacceptable risk, potentially leading to inconsistent actions across countries.
Transparency in supply chains: As recalls increasingly link back to shared ingredients and suppliers, advocates argue for greater disclosure of sourcing and more stringent audits of high‑risk components such as oils and powders used in infant formulas.
Risk communication: Authorities are under pressure to communicate clearly without causing unnecessary panic, balancing precautionary recalls with reassurance that most formula products on the market remain safe.

From a consumer perspective, the incident may fuel demand for clearer labelling, faster notification systems and stronger guarantees around infant food safety. For manufacturers, repeated contamination scares risk reputational damage and could accelerate investments in improved testing technologies and supplier oversight.

Limitations and unanswered questions

Despite the rapid regulatory response, important uncertainties remain. There are currently no widely available definitive clinical laboratory tests for cereulide poisoning, which means suspected cases are often diagnosed based on symptoms and exposure history rather than direct toxin detection. This complicates efforts to estimate how many infants, if any, have been significantly affected.